Mechanism of Action
LPL Inhibition and Triglyceride Partitioning
ANGPTL8 circulates as a monomer but can form heterodimers with ANGPTL3. The ANGPTL3-ANGPTL8 complex inhibits LPL in heart and skeletal muscle more potently than ANGPTL3 alone, reducing non-adipose tissue triglyceride uptake during fed state and directing energy storage to adipose. This "fed-state TG partitioning" role positions ANGPTL8 as a metabolic switch: high during fed state (directing TG to adipose), low during fasting (allowing cardiac/muscle TG uptake).
Beta Cell Proliferation (Disputed)
The original betatrophin report (Yi et al., Cell 2013) showed that ANGPTL8 overexpression expanded mouse beta cell mass ~17-fold. This was not replicated by multiple independent groups, and the mechanism proposed (binding to an unknown receptor on beta cells) was not confirmed. Consensus: ANGPTL8 does not have a major physiological role in beta cell mass regulation, but the controversy drove significant research into its biology and metabolism regulation role.
Research Summary
Triglyceride Metabolism
Active ResearchANGPTL8 knockout mice: lower postprandial triglycerides and reduced adipose TG storage. Human genetic studies: ANGPTL8 variants (R59W) associate with lower TG and higher HDL, confirming the LPL-regulating role. ANGPTL3-ANGPTL8 complex inhibition by evinacumab and antisense oligonucleotides for homozygous familial hypercholesterolemia provides indirect validation.
Metabolic Syndrome and Diabetes
Active ResearchCirculating ANGPTL8 is elevated in obese, insulin-resistant, and T2D subjects, correlating with triglycerides and metabolic syndrome markers. Whether elevated ANGPTL8 is causative or compensatory remains debated. ANGPTL8 inhibition may improve cardiometabolic risk profile by normalizing TG partitioning. In liver regeneration models, ANGPTL8 promotes hepatocyte proliferation -- a distinct hepatotrophic function.
Calculate your Betatrophin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| TG metabolism research | 1-10 mg/kg IV acute lipid challenge models; or adeno-associated viral overexpression | Per session or sustained expression | Intravenous or AAV injection |
The beta cell proliferation application (original "betatrophin" concept) is not supported by replication data. Research focus is on ANGPTL8 LPL inhibitory role in lipid metabolism and liver regeneration.
Interactions
Safety Profile
No human pharmacological data for exogenous ANGPTL8. ANGPTL8 overexpression in mice: increased adiposity and postprandial hypertriglyceridemia, confirming expected TG partitioning effects. No significant organ toxicity reported. The original beta cell expansion report is not a valid basis for therapeutic expectations. ANGPTL8 inhibition (as part of ANGPTL3 blockade with evinacumab) is well tolerated in clinical trials with primary adverse effects of injection site reactions and nasopharyngitis.
References
- [1]Yi P, et al. Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell. 2013;153(4):747-758.
- [2]Gusarova V, et al. ANGPTL8/betatrophin does not control pancreatic beta cell expansion. Cell. 2014;159(3):691-696.
- [3]Wang Y, et al. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun. 2013;432(2):479-483.